A novel theranostics technique uses dual infrared photon laser beams to release chemotherapy within tumor cells for next-generation imaging biomarker and targeted therapy, according to an announcement from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.

A small group of proteins called transcription factors that regulate genetic expression tip off the mother cells of very aggressive and therapy-resistant brain cancer, according to Massachusetts General Hospital research announced by the institution yesterday.

SBRI contract to explore potential of low-cost commercial 3D scanner in healthcare applicationsOxford, UK & Greenville, NC – April 9, 2014 – Fuel 3D Technologies Ltd., developer of 3D scanning solutions, today announced it has secured a £685,831 ($1.1 million) SBRI Healthcare development contract for the development of a 3D medical imaging system. SBRI Healthcare is an NHS England initiative, which aims to promote UK economic growth while addressing unmet health needs and enhancing the take up of known best practice. Fuel 3D Technologies will use the contract to develop its Eykona scanner technology for a range of therapy applications and adoption in the NHS and international healthcare markets.

An international consortium has been awarded a $1.8 million grant from the European Commission to assess Cerenkov luminescence imaging for intraoperative imaging of gastric cancer patients.

A bipartisan bill brought forward in the U.S. House of Representatives April 4 would coordinate an international initiative for the prevention and treatment of Alzheimer’s disease and other dementias.

GE Healthcare announced yesterday that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the company’s PET/CT iterative image reconstruction technology that works to improve image quality and quantitative data.

Shine Medical Technologies based in Monona, Wis., has solidified a deal with GE Healthcare to provide consistent production of molybdenum-99, which decays into technetium-99m—the medical isotope most used throughout the world in nuclear medicine procedures, the company announced last week.

Drug policy in the European Union could change in the not too distant future depending on a vote regarding a law proposed to discourage pharmaceutical companies from playing favorites when it comes to clinical trials.